China Pharma (NYSE:CPHI) Trading 2.5% Higher – What’s Next?

China Pharma Holdings, Inc. (NYSE:CPHI) was up 2.5% on Tuesday . The stock traded as high as $0.8540 and last traded at $0.8410. 117,261 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 1,772,195 shares. The stock had previously closed at $0.8201.

China Pharma Trading Down 2.1%

The firm has a market cap of $32.83 million, a price-to-earnings ratio of -1.77 and a beta of 1.05. The company has a quick ratio of 0.26, a current ratio of 0.79 and a debt-to-equity ratio of 0.22. The business has a 50 day moving average price of $1.15 and a 200-day moving average price of $0.84.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in China Pharma stock. Citadel Advisors LLC boosted its position in shares of China Pharma Holdings, Inc. (NYSE:CPHI) by 31.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,426 shares of the company’s stock after purchasing an additional 7,356 shares during the period. Citadel Advisors LLC owned approximately 0.93% of China Pharma worth $59,000 at the end of the most recent reporting period.

About China Pharma

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.